Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

All-Trans-Retinoic Acid Induction Overcomes Immune Evasion through Downregulating Immune Checkpoint Molecules and Inducing a Cytokine Storm Triggered By Overexpression of S100A8/A9 Signaling

Blood (2023) 142 (Supplement 1): 4335.

https://doi.org/10.1182/blood-2023-184432

Published: 2023

Journal Articles

Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results

Blood (2023) 142 (Supplement 1): 5954.

https://doi.org/10.1182/blood-2023-184959

Published: 2023

Journal Articles

Application of cfDNA-NGS Test in MRD Monitoring of Acute Leukemia Patients with CAR-T Cell Therapy

Juncheng Chen, Qingya Cui, Mengyun Li, Zheng Li, De-Pei Wu, Xiaowen Tang, Hongjie Shen

Blood (2023) 142 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2023-186203

Published: 2023

Journal Articles

Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia

Qian Wu, De-Pei Wu, Suning Chen, Xiaofei Yang, Jingren Zhang, Mengxing Xue, Xueqing Dou, Sheng-Li Xue, Huiying Qiu, Xiaowen Tang, Yue Han, Jianhong Fu, Xuefeng He

Blood (2023) 142 (Supplement 1): 1528.

https://doi.org/10.1182/blood-2023-182749

Published: 2023

Journal Articles

Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes

QI Tan, Zheng Li, Sifan Chen, Qingya Cui, Mengyun Li, Ye Zhao, Feng Chen, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2023-185976

Published: 2023

Journal Articles

Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

Yangzi Li, Sining Liu, Qingya Cui, Lingling Liu, Zheng Li, Wei Cui, Mengyun Li, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6803.

https://doi.org/10.1182/blood-2023-184505

Published: 2023

Journal Articles

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Liqing Kang, Shengli Xue, Xiaowen Tang, Xiaoyan Lou, Chongsheng Qian, Wenjie Gong, Mingzhu Xu, Haixia Zhou, Zhen Yao, Wei Wang, Minghao Li, Nan Xu, Zhou Yu, Suning Chen, Huiying Qiu, Haiping Dai, Yang Xu, Depei Wu, Lei Yu

Blood (2023) 142 (Supplement 1): 3477.

https://doi.org/10.1182/blood-2023-181552

Published: 2023

Journal Articles

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Blood (2023) 142 (Supplement 1): 889.

https://doi.org/10.1182/blood-2023-172615

Published: 2023

Journal Articles

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xuanqi Cao, Zheng Li, Yanming Zhang, Qingya Cui, Yunju Ma, Mengyun Li, Sifan Chen, Jia Yin, Wei Cui, Jia Chen, Aining Sun, Huiying Qiu, Suning Chen, Zhengming Jin, Xiaming Zhu, De-Pei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6959.

https://doi.org/10.1182/blood-2023-185258

Published: 2023

Journal Articles

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Sining Liu, Qingya Cui, Zheng Li, Wei Cui, Mengyun Li, Huiying Qiu, Shengli Xue, Suning Chen, Zhengming Jin, Miao Miao, Yue Han, Ying Wang, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2023-186718

Published: 2023

Journal Articles

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Blood (2023) 142 (15): 1323–1327.

https://doi.org/10.1182/blood.2023020102

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

Jundan Xie, Xiaofei Yang, Xiebing Bao, Hongjie Shen, Jiannong Cen, Li Yao, Xiaohui Hu, Qian Wu, Jingren Zhang, Xuefeng He, Xiaowen Tang, AiNing Sun, Hongchun Qiu, Shengli Xue, Ying Wang, Jianhong Fu, Huiying Qiu, Depei Wu, Suning Chen

Blood (2022) 140 (Supplement 1): 1439–1440.

https://doi.org/10.1182/blood-2022-166384

Published: 2022

Journal Articles

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Qian Wang, Haiping Dai, Wenzhi CAI, Qinrong Wang, Zhu Mingqing, Lingzhi Yan, Yan Yu, Hongjie Shen, Yang Xu, Ying Wang, Miao Miao, Shengli Xue, Yue Han, Xiaowen Tang, Huiying Qiu, Aining Sun, Jinyan Huang, Depei Wu, Suning Chen

Blood (2022) 140 (Supplement 1): 9198–9200.

https://doi.org/10.1182/blood-2022-156862

Published: 2022

Journal Articles

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Haiping Dai, Wei Cui, Hongjie Shen, Qian Wang, Jia Yin, Zheng Li, Depei Wu, Xiaowen Tang

Blood (2022) 140 (Supplement 1): 10345–10346.

https://doi.org/10.1182/blood-2022-166687

Published: 2022

Journal Articles

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Haiping Dai, Yang Lin, Huimin Meng, Qingya Cui, Wenjuan Zhu, Xiaowen Tang, Wei Cui, Depei Wu

Blood (2021) 138 (Supplement 1): 4817.

https://doi.org/10.1182/blood-2021-151587

Published: 2021

Journal Articles

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Suning Chen, Jundan Xie, Xiaofei Yang, Hongjie Shen, Jiannong Cen, Li Yao, Xiaohui Hu, Qian Wu, Jingren Zhang, Hongchun Qiu, Xiaowen Tang, Aining Sun, Shengli Xue, Ying Wang, Huiying Qiu, Depei Wu

Blood (2021) 138 (Supplement 1): 35.

https://doi.org/10.1182/blood-2021-153288

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Wei Cui, Xinyue Zhang, Haiping Dai, Qingya Cui, Jia Yin, Zheng Li, Lei Yu, Liqing Kang, Depei Wu, Xiaowen Tang

Blood (2021) 138 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2021-152565

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Blood (2021) 138 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2021-152927

Published: 2021

Journal Articles

Decitabine in Combination with Fludarabine and Cyclophosphamide As Lymphodepletion Regimen Followed By CD19/CD22 Bispecific Targeted CAR-T Therapy Significantly Improves Survival in Relapsed/Refractory B-ALL Patients: A Pilot Study

Yunju Ma, Changju Qu, Haiping Dai, Sining Liu, Qingya Cui, Wei Cui, Jia Yin, Liqing Kang, Xiaying Lian, Huiying Qiu, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2021) 138 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2021-152041

Published: 2021

Journal Articles

Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma

Yujia Xu, Min Xu, Jiefei Tong, Xiaowen Tang, Jinhao Chen, Xuehan Chen, Zubin Zhang, Biyin Cao, A. Keith Stewart, Michael F. Moran, Depei Wu, Xinliang Mao

Blood (2021) 137 (11): 1478–1490.

https://doi.org/10.1182/blood.2020005199

Published: 2021

Includes: Supplemental data

NARROW

All-Trans-Retinoic Acid Induction Overcomes Immune Evasion through Downregulating Immune Checkpoint Molecules and Inducing a Cytokine Storm Triggered By Overexpression of S100A8/A9 Signaling

Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results

Application of cfDNA-NGS Test in MRD Monitoring of Acute Leukemia Patients with CAR-T Cell Therapy

Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia

Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes

Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Decitabine in Combination with Fludarabine and Cyclophosphamide As Lymphodepletion Regimen Followed By CD19/CD22 Bispecific Targeted CAR-T Therapy Significantly Improves Survival in Relapsed/Refractory B-ALL Patients: A Pilot Study

Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only